

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | |
|---|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

| | | | |
|--|---|---|--|
| 1. Name and Address of Reporting Person* <u>Utter Christine Marie</u> (Last) (First) (Middle) <u>C/O PTC THERAPEUTICS, INC.</u> <u>100 CORPORATE COURT</u> (Street) <u>SOUTH</u> <u>PLAINFIELD</u> <u>NJ</u> <u>07080</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>06/02/2017</u> | 3. Issuer Name and Ticker or Trading Symbol (Check all applicable) <u>PTC THERAPEUTICS, INC.</u> [<u>PTCT</u>] | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <u>X</u> Officer (give title below) Other (specify below) <u>Principal Financial Officer</u> | 5. If Amendment, Date of Original Filed (Month/Day/Year) |
| | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <u>X</u> Form filed by One Reporting Person Form filed by More than One Reporting Person |

| Table I - Non-Derivative Securities Beneficially Owned | | | |
|--|--|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| <u>Common Stock</u> | <u>5,297⁽¹⁾</u> | <u>D</u> | |

| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | |
|---|--|--------------------|--|----------------------------------|---|--|--|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| <u>Stock Option (Right To Buy)</u> | <u>(2)</u> | <u>04/27/2021</u> | <u>Common Stock</u> | <u>74</u> | <u>490.8</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(2)</u> | <u>01/10/2022</u> | <u>Common Stock</u> | <u>21</u> | <u>218.4</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(2)</u> | <u>05/15/2023</u> | <u>Common Stock</u> | <u>1,150</u> | <u>10.85</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(3)</u> | <u>01/28/2024</u> | <u>Common Stock</u> | <u>3,369</u> | <u>27.05</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(4)</u> | <u>09/23/2024</u> | <u>Common Stock</u> | <u>4,688</u> | <u>40.45</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(5)</u> | <u>01/02/2025</u> | <u>Common Stock</u> | <u>17,800</u> | <u>51</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(6)</u> | <u>01/03/2026</u> | <u>Common Stock</u> | <u>11,000</u> | <u>30.86</u> | <u>D</u> | |
| <u>Stock Option (Right To Buy)</u> | <u>(7)</u> | <u>01/02/2027</u> | <u>Common Stock</u> | <u>12,600</u> | <u>11.23</u> | <u>D</u> | |

Explanation of Responses:

1. Includes 3,900 shares of Restricted Stock Units awarded to the Reporting Person, which vests in four equal annual installments over four years, commencing on January 3, 2018.
2. Currently exercisable.
3. This option was granted on January 28, 2014 and vests over four years, with 25% of the shares underlying the option vested on January 28, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 28, 2015.
4. This option was granted on September 23, 2014 and vests over four years, with 25% of the shares underlying the option vested on September 23, 2015, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on December 23, 2015.
5. This option was granted on January 2, 2015 and vests over four years, with 25% of the shares underlying the option vested on January 2, 2016, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2016.
6. This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017.
7. This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018.

Remarks:

Avraham S. Adler, attorney-in-fact
** Signature of Reporting Person

06/06/2017
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Donald Mankoff, Mark Boulding, Colleen Diver Johnson, Avraham Adler & (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of PTC Therapeutics, Inc. (the "Company"), Forms 3, 4, (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in fact, may be of benefit to, in the best interests of the Company. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, and proper to carry out the foregoing purposes, and This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's securities.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 6th day of June, 2017.

/s/Christine Utter
Signature

Christine Utter
Print Name